Consensus statement
Updated consensus statement on tumour necrosis factor blocking agents for the treatment of rheumatoid arthritis (May 2000)
| The first 150 words of the full text of this article appear below. |
As last year, a consensus group to consider the use of tumour necrosis factor (TNF) blocking agents was formed by an organising committee constituted of rheumatologists from the Universities of Erlangen, Leiden and Vienna in Europe in cooperation with universities in the United States. Pharmaceutical support was obtained from a number of companies, but these institutions had no part in the decisions regarding this specific programme nor with regard to the participants or attendees at this conference.
The approximately 100 rheumatologists and bioscientists from 25 countries who attended the consensus conference were chosen from a worldwide group of people felt to have experience or interest in the use of TNF blocking treatment for rheumatoid arthritis (RA). Unfortunately, the number of attendees and participants were limited so that not everyone who might have been appropriate could be invited.
During the past year increasing amounts of data on the use of TNF
blocking agents
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
This article has been cited by other articles:
-
Han, M.-K., Kim, J.-S., Park, B.-H., Kim, J.-R., Hwang, B.-Y., Lee, H.-Y., Song, E.-K., Yoo, W.-H.
(2003). NF-{kappa}B-dependent lymphocyte hyperadhesiveness to synovial fibroblasts by hypoxia and reoxygenation: potential role in rheumatoid arthritis. J. Leukoc. Biol.
73: 525-529
[Abstract] [Full Text] -
Barrera, P., van der Maas, A., van Ede, A. E., Kiemeney, B. A. L. M., Laan, R. F. J. M., van de Putte, L. B. A., van Riel, P. L. C. M.
(2002). Drug survival, efficacy and toxicity of monotherapy with a fully human anti-tumour necrosis factor-{alpha} antibody compared with methotrexate in long-standing rheumatoid arthritis. Rheumatology (Oxford)
41: 430-439
[Abstract] [Full Text] -
(2001). {blacktriangledown}Etanercept and {blacktriangledown}infliximab for rheumatoid arthritis. DTB
39: 49-52
[Abstract] [Full Text]
- Full Text
- Full Text (PDF)
- Submit a response
- Alert me when this article is cited
- Alert me when eLetters are posted
- Alert me if a correction is posted
- Citation Map
Services
- Email this link to a friend
- Similar articles in this journal
- Similar articles in PubMed
- Add article to my folders
- Download to citation manager
- Request Permissions
Citing Articles
Google Scholar
PubMed
Bookmark with
Register for free content
The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.
Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.
